Avita Medical, Inc. Common Stock

The global scar treatment market is projected to grow from USD 26.60 billion in 2025 to USD 56.30 billion by 2033, with a CAGR of 9.91%. Growth is driven by increasing awareness of advanced cosmetic and reconstructive procedures, rising prevalence of acne, surgical, and traumatic scars, and technological advancements in minimally invasive treatme...

AVITA Medical presented 19 scientific abstracts at the 2026 Boswick Burn & Wound Symposium, including the first surgeon-reported integrated use of its three technologies (RECELL, PermeaDerm, and Cohealyx) in patient cases. New clinical and histological data demonstrated that RECELL use was associated with smaller donor sites, faster healing times...

Law firm Bragar Eagel & Squire is investigating potential securities violations at three companies: Soleno Therapeutics following a report questioning its product's safety and pricing, AVITA Medical due to significant claim payment backlogs affecting product utilization, and Coty following unexpected losses and disappointing guidance attributed t...

AVITA Medical announced Cary Vance as Interim CEO, replacing Jim Corbett. The company expects Q3 2025 revenue of approximately $17 million and is seeking a permanent CEO through an executive search.

Law firm investigating potential claims against AVITA Medical after company reported significant backlog of unpaid provider claims for Recell procedures, causing stock price to decline by 21%.